House dust mite–specific immunoglobulin G (HDM-specific IgG)

House dust mite–specific immunoglobulin G (HDM-specific IgG) refers to a population of antibodies, predominantly of the IgG4 subclass, that are induced in patients undergoing allergen-specific immunotherapy (AIT) for house dust mite allergies. These antibodies function as 'blocking antibodies' by binding to major HDM allergens, such as Der p 1 and Der p 2, with high affinity, thereby competing with allergen-specific IgE for binding sites (Akdis & Akdis, 2014; PubMed: 24943118). By intercepting allergens before they can cross-link IgE on the surface of mast cells and basophils, HDM-specific IgG prevents the release of histamine and other inflammatory mediators. This process is a hallmark of the shift from a Th2-dominated allergic response to a more regulatory immune profile. In clinical practice, the elevation of serum HDM-specific IgG4 is used as a primary biomarker to monitor the immunological efficacy of sublingual (SLIT) or subcutaneous (SCIT) immunotherapy (Shamji & Durham, 2017; PubMed: 28212932). While HDM-specific IgG is a product of the immune system's response to treatment rather than a direct drug target, its induction is essential for achieving long-term clinical desensitization in patients with allergic rhinitis and asthma. Monitoring these antibody levels provides biotech analysts and clinicians with measurable evidence of the treatment's impact on the patient's underlying allergic pathology.

Other names

HDM-specific IgGHDM-specific IgG4House dust mite blocking antibodiesHDM-sIgG4Mite-specific IgG

Induction of allergen-specific IgG (primarily the IgG4 subclass) which acts as a blocking antibody to compete with IgE for allergen binding sites, thereby preventing the cross-linking of IgE on mast cells and basophils (Shamji & Durham, 2017; PubMed: 28212932).